Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

Simple eye scan can detect early signs of diabetes-related nerve damage

Simple eye scan can detect early signs of diabetes-related nerve damage

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

China's SFDA approves TPI anti-diabetic drug Gliclazide

China's SFDA approves TPI anti-diabetic drug Gliclazide

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Millennium submits two VELCADE sNDAs to FDA

Millennium submits two VELCADE sNDAs to FDA

New experimental drug can help treat peripheral neuropathy in cancer patients

New experimental drug can help treat peripheral neuropathy in cancer patients

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

CDA launches new awareness campaign about risk of developing type 2 diabetes

CDA launches new awareness campaign about risk of developing type 2 diabetes

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept 2010 fourth quarter net loss is $0.06 per share

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.